March 16, 2021
1 min read
Save
Stuart Raetzman appointed as interim CEO at TearClear
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
TearClear has appointed Stuart Raetzman as interim CEO and is preparing for a pivotal study on proprietary latanoprost for glaucoma treatment, according to a press release.
“TearClear thanks Robert Dempsey for his contributions and wishes him well. We are excited for the company’s next chapter as we scale our platform and advance our innovative ophthalmic pharmaceutical portfolio. At TearClear, our goal is to disrupt the way current topical medications are delivered to the ocular surface,” Raetzman, a TearClear board member, said in the release.
TearClear plans to submit an investigational new drug application to the FDA later this year following a successful pre-IND meeting in November, the release said.
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.